Identification of potential glycoprotein biomarkers in oral squamous cell carcinoma using sweet strategies

• Main Authors: Wong, Yin Ling, Anand, Ramanathan, Yuen, Kar Mun, Mustafa, Wan Mahadzir Wan, Abraham, Mannil Thomas, Tay, Keng Kiong, Rahman, Zainal Ariff Abdul, Chen, Yeng
• Format: Article
• Published: Springer 2021
• Subjects: RK Dentistry
• Online Access: http://eprints.um.edu.my/25925/; https://doi.org/10.1007/s10719-021-09973-z
• Institution: Universiti Malaya

The prevalence of oral squamous cell carcinoma (OSCC) is high in South and Southeast Asia regions. Most OSCC patients are detected at advanced stages low 5-year survival rates. Aberrant expression of glycosylated proteins was found to be associated with malignant transformation and cancer progression. Hence, identification of cancer-associated glycoproteins could be used as potential biomarkers that are beneficial for diagnosis or clinical management of patients. This study aims to identify the differentially expressed glycoproteins using lectin-based glycoproteomics approaches. Serum samples of 40 patients with OSCC, 10 patients with oral potentially malignant disorder (OPMD), and 10 healthy individuals as control group were subjected to two-dimensional gel electrophoresis (2-DE) coupled with lectin Concanavalin A and Jacalin that specifically bind to N- and O-glycosylated proteins, respectively. Five differentially expressed N- and O-glycoproteins with various potential glycosylation sites were identified, namely N-glycosylated α1-antitrypsin (AAT), α2-HS-glycoprotein (AHSG), apolipoprotein A-I (APOA1), and haptoglobin (HP); as well as O-glycosylated AHSG and clusterin (CLU). Among them, AAT and APOA1 were further validated using enzyme-linked immunosorbent assay (ELISA) (n = 120). It was found that AAT and APOA1 are significantly upregulated in OSCC and these glycoproteins are independent risk factors of OSCC. The clinical utility of AAT and APOA1 as potential biomarkers of OSCC is needed for further evaluation. © 2021, The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.